<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01884428</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-2010-003</org_study_id>
    <secondary_id>2010-022452-23</secondary_id>
    <nct_id>NCT01884428</nct_id>
  </id_info>
  <brief_title>Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma</brief_title>
  <official_title>Phase I, Prospective, Open-label, Multi-centric, Dose Finding Trial of Combination of IGEV and Panobinostat Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Armando Santoro, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      study to assess maximum tolerated dose (MTD), safety, tolerability and activity of IGEV
      (Ifosfamide, Gemcitabine,Vinorelbine, Prednisolone) + Panobinostat new combination in order
      to determine the recommended phase II dose
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will received 4 p-IGEV courses repeated every 3 weeks in the absence of unacceptable
      toxicity, whenever an objective response is observed at disease evaluation performed after II
      cycle.

      Eligible patients will be accrued in cohorts of 3 patients at each dose level and dose
      escalation will be performed following the standard 3+3 rule.

      Three patients will be treated for each dose-level, starting from level 1, for one cycle: if
      no dose-limiting toxicities (DLTs) will be recorded after the first cycle, treatment will be
      continued in those patients until study completion or unacceptable toxicity and three new
      patients will be treated at the next dose level. However, if one out of 3 patients will
      develop a DLT, the same dose-level will be administered to three additional patients for one
      cycle. If no one of those additional patients will experience a DLT, dose escalation will
      continue. If more than one over 3 or 6 patients will develop a DLT after the first cycle in
      any cohort, MTD will be reached. Six further patients will be treated at the lower dose in
      order to obtain more information about the optimal dose for phase II trials and to
      characterize pharmacokinetic profiles of this combination. If DLT will be found at level 1
      (20 mg), 3 patients will be treated at dose -1 (10 mg). If no more than 1 patient experience
      toxicity, other 3 patients will be treated to assess more information about pharmacokinetic
      profiles and safety.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) or the recommended phase II dose defined as the highest dosage cohort at which no more than one of six patients will experience a DLT in the first treatment cycle.</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DLT</measure>
    <time_frame>3 weeks</time_frame>
    <description>Incidence of dose limiting toxicities (DLTs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety profile</measure>
    <time_frame>3 months</time_frame>
    <description>Preliminary safety profile defined as Adverse Events (AEs), Serious Adverse Events ( SAEs) &amp; Changes in Clinical Laboratory Evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response and Overall Response Rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematologic toxicity</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of neutropenia and thrombocytopenia incidence, duration, as well as platelet transfusion requirement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD34+ cells count</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of number of CD34+ collected and number of leukapheresis required to obtain an appropriate collection according to transplant program.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy of PIGEV combination in terms of progression-free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Panobinostat + IGEV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Panobinostat + IGEV regimen (Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>panobinostat</intervention_name>
    <description>Dose excalation oral panobinostat 3 days a week for a maximum of 4 cycles of three weeks duration</description>
    <arm_group_label>Panobinostat + IGEV</arm_group_label>
    <other_name>LBH-589</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Ifosfamide 2000 mg/m2 on days 1 to 4 as a 2-hour infusion for a maximum of 4 cycles of three weeks duration</description>
    <arm_group_label>Panobinostat + IGEV</arm_group_label>
    <other_name>Ifex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 800 mg/m2 on days 1 and 4 for a maximum of 4 cycles of three weeks duration</description>
    <arm_group_label>Panobinostat + IGEV</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinorelbine 20 mg/m2 on day 1 for a maximum of 4 cycles of three weeks duration</description>
    <arm_group_label>Panobinostat + IGEV</arm_group_label>
    <other_name>Navelbine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone 100 mg on days 1 to 4 for a maximum of 4 cycles of three weeks duration</description>
    <arm_group_label>Panobinostat + IGEV</arm_group_label>
    <other_name>Prelone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of relapsed or refractory classical HL

          -  Measurable disease

          -  One or two prior systemic lines of treatment

          -  PS(ECOG) 0-2

          -  Absence of bone marrow infiltration

          -  Adequate laboratory values for bone marrow, liver and renal functionality

        Exclusion Criteria:

          -  prior or concurrent treatment with a DAC inhibitor including panobinostat

          -  valproic acid therapy for any medical condition during the study or within 5 days
             prior to the first panobinostat treatment

          -  previous autologous hematopoietic stem cell transplant

          -  other concurrent therapy intended to treat the primary cancer including chemotherapy,
             investigational or biologic agents or other antitumor agents

          -  impaired cardiac function or unstable AF

          -  known history of HIV seropositivity, chronic hepatitis, or other active viral
             infections

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of panobinostat (e.g., ulcerative disease, uncontrolled nausea,
             vomiting, diarrhea, malabsorption syndrome, obstruction, or stomach and/or small bowel
             resection)

          -  pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armando Santoro, MD</last_name>
    <phone>+39 (0)2 8224</phone>
    <phone_ext>4080</phone_ext>
    <email>armando.santoro@humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rita Mazza, MD</last_name>
    <phone>+39 (0)2 8224</phone>
    <phone_ext>4780</phone_ext>
    <email>rita.mazza@humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Santoro, MD</last_name>
      <phone>+39 (0)2 8224</phone>
      <phone_ext>4080</phone_ext>
      <email>armando.santoro@humanitas.it</email>
    </contact>
    <contact_backup>
      <last_name>Rita Mazza, MD</last_name>
      <phone>+39 (0)2 8224</phone>
      <phone_ext>4780</phone_ext>
      <email>rita.mazza@humanitas.it</email>
    </contact_backup>
    <investigator>
      <last_name>Armando Santoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita Mazza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2013</study_first_submitted>
  <study_first_submitted_qc>June 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2013</study_first_posted>
  <last_update_submitted>January 28, 2014</last_update_submitted>
  <last_update_submitted_qc>January 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Armando Santoro, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Hodgkin</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Panobinostat</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

